Madrigal Pharmaceuticals, Inc. (MDGL)
434.24
-19.10
(-4.21%)
USD |
NASDAQ |
Oct 23, 16:00
437.68
+3.44
(+0.79%)
After-Hours: 20:00
Madrigal Pharmaceuticals Enterprise Value : 9.537B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 9.537B |
| October 22, 2026 | 9.978B |
| October 21, 2026 | 10.08B |
| October 20, 2026 | 10.31B |
| October 19, 2026 | 9.834B |
| October 16, 2026 | 9.895B |
| October 15, 2026 | 10.13B |
| October 14, 2026 | 10.13B |
| October 13, 2026 | 9.950B |
| October 12, 2026 | 10.30B |
| October 09, 2026 | 10.40B |
| October 08, 2026 | 10.52B |
| October 07, 2026 | 10.77B |
| October 06, 2026 | 10.97B |
| October 05, 2026 | 10.91B |
| October 02, 2026 | 11.04B |
| October 01, 2026 | 11.05B |
| September 30, 2026 | 11.15B |
| September 29, 2026 | 11.27B |
| September 28, 2026 | 11.45B |
| September 25, 2026 | 11.44B |
| September 24, 2026 | 11.36B |
| September 23, 2026 | 11.36B |
| September 22, 2026 | 11.49B |
| September 21, 2026 | 11.56B |
| Date | Value |
|---|---|
| September 18, 2026 | 11.78B |
| September 17, 2026 | 11.85B |
| September 16, 2026 | 11.73B |
| September 15, 2026 | 11.59B |
| September 14, 2026 | 11.98B |
| September 11, 2026 | 11.85B |
| September 10, 2026 | 11.82B |
| September 09, 2026 | 12.13B |
| September 08, 2026 | 11.84B |
| September 04, 2026 | 12.00B |
| September 03, 2026 | 12.04B |
| September 02, 2026 | 12.14B |
| September 01, 2026 | 11.95B |
| August 31, 2026 | 11.98B |
| August 28, 2026 | 11.84B |
| August 27, 2026 | 12.06B |
| August 26, 2026 | 11.95B |
| August 25, 2026 | 11.34B |
| August 24, 2026 | 11.33B |
| August 21, 2026 | 11.44B |
| August 20, 2026 | 11.50B |
| August 19, 2026 | 11.98B |
| August 18, 2026 | 11.62B |
| August 17, 2026 | 11.63B |
| August 14, 2026 | 11.23B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Cytokinetics, Inc. | 8.598B |
| Insmed, Inc. | 19.97B |
| United Therapeutics Corp. | 22.41B |
| Karyopharm Therapeutics, Inc. | 202.82M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.94M |
| Revenue (Quarterly) | 364.25M |
| Total Expenses (Quarterly) | 422.19M |
| EPS Diluted (Quarterly) | -1.988 |
| Gross Profit Margin (Quarterly) | 88.91% |
| Profit Margin (Quarterly) | -15.91% |
| Earnings Yield | -2.97% |
| Normalized Earnings Yield | -2.947 |